Uncategorized

FDA’s radical transparency policy for rejections runs into legal uncertainty

FDA’s radical transparency policy for rejections runs into legal uncertainty

Published

on

Having started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version